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Abstract. Starting from an adequate ketone precursor 
previous reports required three step for the preparation of 
(R)-2,3,4,9-tetrahydro-1H-carbazol-3-amine, a key 
intermediate for the synthesis of the anti allergic drug 
Ramatroban. A single biocatalytic step was sufficient to 
prepare the target amine with >97% ee (HPLC) via 
reductive amination of the corresponding ketone using a -
transaminase as biocatalyst. Since the ketone was barely 
soluble under the reaction conditions employed, it was 
provided as a solid and still the reaction went to completion 
within 4 hours at 50 mM substrate concentration. Although 
2-propylamine is regarded as an ideal amine donor, it 
turned out to be detrimental for the specific ketone 
precursor leading to the formation of various side products. 
These could be avoided by using (R)-1-phenylethylamine 
as the best suited amine donor. An alternative work up was 
developed via freeze drying of the reaction mixture, 
enabling the isolation of the desired (R)-amine in excellent 
yield (96%) and enantiopure form on a preparative scale 
(500 mg). No purifications step (e.g. column 
chromatography, crystallization) was required.  
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(R)-Ramatroban, Baynas® (R)-1 is employed for 
the treatment of allergic rhinitis and asthma but also 
shows promising applications for the treatment of 
coronary artery diseases.[1] Since exclusively the (R)-
enantiomer is linked to the pharmacological 
activity,[2] efficient asymmetric routes for its 
preparation are required. 
To date, the preparation of the enantiomerically 
pure drug has been described by the formation of 
diastereomeric salts[3] or asymmetric Fischer 
indolization using chiral phosphoric acids.[4] Since 
biocatalysis offers various methods to prepare 
pharmaceutically active ingredients or natural 
products[5] e.g. employing hydrolases,[6] the 
chemoenzymatic synthesis of Ramatroban has been 
reported using lipases or oxidoreductases for the 
asymmetric key step, giving the enantioenriched 
alcohol (S)-3 (Scheme 1).[7] The main drawback of 
this route results from the Mitsunobu inversion of the 
alcohol to afford the amine (R)-4 which is prone to 
racemization. Moreover, large excesses of various 
reagents such as diethyl azodicarboxylate (DEAD), 
diphenylphosphoryl azide (DPPA) or triphenyl 
phosphine (PPh3) are required, whereby some require 
special handling. Consequently, this step is the main 
limitation to establish an industrial chemoenzymatic 
process where the production of intermediates on a 






























Scheme 1. Key steps of the published chemoenzymatic synthesis of (R)-Ramatroban involving the asymmetric bio 
reduction of the ketone 2 and the Mitsunobu inversion of the alcohol (S)-3 to afford the enantiopure amine (R)-4.[7] 
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As an alternative the direct asymmetric amination 
of the prochiral ketone 2 is described here employing 
-transaminases (-TAs, EC 2.6.1.x).[8,9] -TAs 
have been used already successfully for the 
preparation of pharmaceutical compounds[10] or 
natural products[11] even on a multi-kg scale.[12]  
The amination of the ketone 2 was initially studied 
at a 25 mM substrate concentration using a set of -
TAs overexpressed in E. coli: the (R)-selective ω-
TAs from (R)-Artrhobacter,[13]  Hyphomonas 
neptunium[14]  and Aspergillus terreus and the (S)-
selective ω-TAs from Bacillus megaterium,[15] Vibrio 
fluvialis,[16]  Arthrobacter citreus,[17] and 
Chromobacterium violaceum[18]  (Scheme 2). D- and 
L-alanine, respectively were initially used as amine 
source. The equilibrium was shifted towards product 
formation by removing/recycling the pyruvate to L-
alanine with an alanine dehydrogenase (AlaDH) at 
the expense of ammonia and formate.[19] 
 
Scheme 2. Amination of ketone 2 employing -
transaminases (-TA). Pyruvate was removed/recycled to 
L-alanine employing an alanine dehydrogenase; formate 
dehydrogenase was employed for NADH recycling; PLP: 
pyridoxal-5’-phosphate. 
From the (S)-selective ω-TAs tested only the ω-TA 
from A. citreus and C. violaceum were active leading 
to complete consumption of the ketone after 24 h 
(Table 1). While A. citreus displayed a moderate 
enantiopreference (66% ee, entry 1), a perfect ee 
>97% (HPLC) was obtained with C. violaceum (entry 
2). The amination was performed on preparative scale 
isolating (S)-4 in enantiopure form and good isolated 
yield (62%).  
Table 1. Biocatalytic reductive amination of 2 employing 
ω-TAs and L-alanine as amine donor.  
Entry ω-TA Conv. 
[%][a] 
4 [%][b] ee 4 
[%][d] 
1 A. citreus >97 90 66 (S) 
2 C. violaceum >97 93 (62)[c] >97 (S) 
[a] Measured by GC-FID. Reaction conditions: phosphate 
buffer (100 mM, pH 7), ketone 2 (25 mM), lyophilised 
cells E. coli/ω-TA (30 mg), PLP (1 mM), NAD+ (1 mM), 
D- or L-alanine (10 equiv.), Ala-DH (11 U), FDH (11 U), 
ammonium formate (150 mM), 24 h at 30 ºC and 750 rpm. 
[b] An unidentified side product was formed, therefore the 
percentage of 4 is lower than the conversion. [c] Isolated 
yield in brackets. [d] Determined for the corresponding 
acetamide by HPLC on a chiral phase. 
It is worth mentioning that the substrate 2 was 
barely soluble in buffer (1.6 mM), thus at 25 mM 
calculated substrate concentration most of the ketone 
2 was present as a solid, consequently it is 
remarkably that the transformation worked so well 
for both (S)-enzymes. 
Unfortunately, none of the (R)-selective -TAs of 
the first set of enzymes transformed ketone 2 
providing access to the target amine (R)-4. 
Consequently, a variant of (R)-Arthrobacter 
(ArRmut11-ω-TA) was tested, which was developed 
for the amination of sterically hindered ketones.[12b] 
This enzyme was evolved to show an improved 
thermal stability and is described to preferentially 
accept 2-propylamine as amine donor. Consequently 
2-propylamine was employed in excess (500 mM) to 
shift the equilibrium towards the formation of the 
amine 4 at 45 °C (Scheme 3). 
 
Scheme 3. Single enzyme asymmetric amination of ketone 
2 using ArRmut11-ω-TA. 
 
After 24 h the ketone 2 was completely consumed, 
obtaining the amine (R)-4 in enantiopure form 
although with low isolated yield (26%, Table 2, entry 
1), due to the formation of side products, which were 
isolated and characterized by NMR and mass 
spectroscopy. These products were identified as a 
mixture of the phenol 5 and isopropylamino carbazol 
6 (see SI for details). The formation of 5 can be 
rationalized by base promoted formation of the 
enolate and the subsequent spontaneous 
aromatization. The second side-product, the 
isopropylamino carbazol 6, can be explained by the 
formation of the corresponding enamine followed by 
spontaneous aromatization. Trying to improve the 
yield for the target (R)-4, we considered the use of 
different organic co-solvents, which might help also 
with respect to the low solubility of the substrate. 
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However, the addition of a miscible organic co-
solvent such as DMSO favoured the formation of the 
enamine leading to even lower isolated yields (entry 
2). On the other hand, better results were obtained 
with a non-miscible solvent such as EtOAc where the 
organic phase acts as a reservoir for the ketone 
reducing the formation of side products but slowing 
down the overall reaction (entry 3). 
Table 2. Reductive amination of 2 employing ArRmut11-
ω-TA and 2-propylamine (500 mM) as amine donor.  
Entry Co-solvent 4 [%][a] ee 4 [%][b] 
1 -- 26 >97 (R) 
2 10% DMSO 9 >97 (R) 
3 10% EtOAc  43 >97 (R) 
[a] Isolated yields after flash chromatography. Reaction 
conditions: ketone (4.6 mg, 25 mM), lyophilised cells 
containing ArRmut11-ω-TA (30 mg), PLP (0.5 mM), 2-
propylamine (500 mM), after 24 h at 30 ºC and 750 rpm. [b] 
Determined for the corresponding acetamide by HPLC on 
a chiral phase. 
To minimise or even avoid the formation of the 
side-products 5 and 6, (R)-1-phenylethylamine (R)-7 
as a sterically more demanding amine donor was 
investigated. Due to its bulkiness and lower basicity, 
less base catalysed enol formation as well as also less 
enamine formation was expected. Additionally, the 
deamination of (R)-7 is thermodynamically favoured 
meaning that a lower excess of the amine donor 
should be required.[20] 
Optimization of the biocatalytic amination of 2 was 
performed at 45 °C in phosphate buffer at pH 7 at 
varied concentrations of the starting ketone and the 
amine donor (Table 3). The reaction was first 
performed at a 25 mM substrate concentration 
employing 4 equivalents of (R)-7 as amine source. 
Employing a semi purified enzyme preparation (heat 
treatment) of ArRmut11-ω-TA all the starting 
material was exclusively transformed into the desired 
amine (R)-4 already after 4 h (entry 1). The amine 
was isolated after flash chromatography in good yield 
and enantiopure form. However, a significant mass 
loss (24%) was noticed during the 
isolation/purification steps. For that reason, we 
designed an alternative work-up procedure. Instead of 
extraction after basification, the crude reaction was 
alkalinized and freeze-dried to remove the water. The 
so obtained powder was suspended in a CH2Cl2/EtOH 
mixture and filtered through Celite®, then the solvent 
was removed under reduced pressure. Using this 
protocol (R)-4 was obtained in enantiopure form with 
95% isolated yield and excellent chemical purity (see 
supporting information for NMR data), without any 
additional purification step (entry 2). 
When reducing the equivalents of amine donor to 
make the process more attractive, 2 equivalents of 
(R)-7 were found to be the optimum (entries 3 and 4). 
Below this level, longer reaction times were noticed 
leading also to the formation of trace amounts of side 
products. In a next step, the substrate concentration 
was increased. Finally at 50 mM substrate 
concentration the amine was still isolated in excellent 
yield, enantiopure form and without the formation of 
side products (entry 5). 
Table 3. Reductive amination of 2 employing ArRmut11-
ω-TA and varied concentrations of (R)-1-phenylethylamine 
7 as amine donor at 45 °C and pH 7 after 4 h. 
Entry Ketone (mM) Eqs. 7 4 [%] ee 4 [%][c] 
1 25 4 76[a] >97 (R) 
2 25 4 95[b] >97 (R) 
3 25 3 90[b] >97 (R) 
4 25 2 94[b] >97 (R) 
5 50 2 95[b] >97 (R) 
[a] Isolated yields after flash chromatography. [b] Isolated 
yields after alternative work-up. [b] Determined by HPLC 
on a chiral phase of the acetamide derivative. 
The synthetic applicability of the approach was 
demonstrated on a 500 mg scale (2.70 mmol, 50 mM) 
with just 0.5 mM PLP. The enantiopure amine (R)-4 
was obtained in 96% isolated yield and enantiopure 
form (>97% ee). 
Finally, the reductive amination was compared with 
the “old chemoenzymatic route” that involves the 
bioreduction of the ketone 2 and the Mitsunobu 
inversion (Figure 1).[7]  
 
Figure 1. Comparison between the biocatalytic amination 
and the chemoenzymatic route (ADH reduction plus 
Mitsunobu) in terms of optical purity, time, yield, E-factor 
and number of steps. 
The biocatalytic amination provides access to the 
enantiopure amine within only 4 h, while a longer 
reaction time (50 h) and three steps were required in 
the previous approach. Additionally, higher yields 
were obtained with the present route (96% versus 
62%) not requiring a chromatographic purification of 
the amine. In terms of waste production the E-
factor[21]  defined as total waste (kg)/product (kg) 
diminished since over-stoichiometric reagents were 
minimized (see SI for details). Moreover, the direct 
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amination is much more attractive from an 
environmental point of view since the amination is 
performed in aqueous buffer avoiding the use of 
hazardous reagents such as DPPA or DEAD. 
In summary, an efficient one-step protocol was 
developed for the amination of ketone 2 to the 
enantiopure amine (R)-4, which is a key intermediate 
for the synthesis of the anti allergic drug Ramatroban. 
The practical applicability of the approach has been 
demonstrated performing the amination on a 500 mg 
scale affording the enantiopure amine with excellent 
chemical purity and very high isolated yield (96%). 
Last but not least, the total yield of the formal total 
synthesis of the drug has been significantly improved 
from 30% in the previous route to 50% and the 
number of steps was reduced from 6 to 4. 
Experimental Section 
All starting materials were obtained from commercial 
suppliers and were used as received. TLC analyses were 
carried out with precoated aluminium sheets (TLC silica 
gel 60 F254, Merck) with detection by UV or staining with 
potassium permanganate. Preparative chromatographic 
separations were performed by flash chromatography on 
Merck silica gel (0.063-0.200 μm). Optical rotation was 
measured at 20 °C with a Perkin-Elmer polarimeter at the 
sodium D-line. GC-MS spectra were recorded with an 
Agilent 7890A GC system mass selective detector and HP-
5 MS column [30 m  0.25 mm  0.25 μm; helium as 
carrier gas (flow = 0.55 mL/min)]. 1H and 13C NMR 
spectra were recorded at 20 °C with a Bruker 300 MHz 
unit; chemical shifts are given in ppm relative to the 
resonance of the solvent. Formate dehydrogenase from 
Candida boidinii catalogue no. FDH 002 [lyophilised 
powder 2.2 U/mg] and NAD+ free acid were purchased 
from Codexis. Lyophilised E. coli cells containing 
overexpressed ω-transaminases were prepared as 
previously reported.[13a,22] Activity for alanine dependent 
ω-TAs and ArRmut11 was determined for the deamination 
of (R)- or (S)-1-phenylethanamine with pyruvate. Purified 
L-alanine dehydrogenase was prepared as described 
recently.[12a] Small scale reactions were shaken in 2 mL 
thermo shaker Eppendorf® Comfort. Preparative scale 
reactions were performed in an Infors Unitron shaker. 
Biotransformations (AlaDH; analytical scale): The 
ketone 2 (4.6 mg, 25 μmol) was suspended in K-phosphate 
buffer (pH 7, 100 mM, 550 μL) and the following reagents 
dissolved in K-phosphate buffer (pH 7, 100 mM) were 
added: L-alanine (250 μL, 1 M), NH4HCOO (150 μL, 1.5 
M), PLP (20 μL, 50 mM), NAD+ (20 μL, 50 mM) Ala-DH 
(10 μL, 11 U) FDH (5 mg, 11 U) and the lyophilised cells 
containing ω-TA (30 mg). The reductive amination was 
carried out at 30 °C in an orbital shaker (750 rpm, 
Eppendorf thermo shaker) for 24 h. After that time the 
reaction was stopped by adding a saturated solution of 
Na2CO3 (300 μL). The crude was extracted with CH2Cl2 (2 
 700 μL), dried over Na2SO4 and injected in the GC for 
conversion measurement. 
Biotransformations (2-propylamine; analytical scale): 
The ketone 2 (4.6 mg, 25 μmol) was suspended in a K-
phosphate buffer (pH 7, 100 mM, 750 μL) containing PLP 
(0.5 mM) and 2-propylamine (0.75 M). Then, semi 
purified ArRmut11-ωTA (250 μL) was added and the 
mixture was shaken at 45 °C in an Eppendorff thermo 
shaker (750 rpm,) for 24 h. The reaction was quenched and 
worked-up as described above. 
Biotransformations [(R)-1-phenylethylamine; analytical 
scale]: The ketone 2 (4.6 mg, 25 μmol) was suspended in 
K-phosphate buffer (pH 7, 100 mM, 750 μL) containing 
PLP (0.5 mM) and different concentrations of (R)-1-
phenylethylamine. Then, semi purified ArRmut11-ωTA 
(250 μL) was added to the suspension and the mixture was 
shaken at 45 °C in an Eppendorff thermo shaker (750 rpm) 
for 4 h. The reaction was quenched and worked-up as 
described above. 
Biotransformations on preparative scale using ω-TA 
from C. violaceum: The ketone 2 (27.6 mg, 149 μmol) 
was suspended in K-phosphate buffer (pH 7, 100 mM, 3.3 
mL) and the following aqueous solutions were added to the 
suspension: L-alanine (1.5 mL, 1 M), NH4HCOO (900 μL, 
1.5 M), PLP (120 μL, 50 mM), NAD+ (120 μL, 50 mM) 
Ala-DH (100 μL 110 U) FDH (50 mg, 110 U) and the 
lyophilised cells containing ω-TA (180 mg). The reductive 
amination was carried out at 30 °C in a 15 mL Falcon tube 
and shaken in an Infors orbital shaker (120 rpm) for 24 h. 
After that time the reaction was stopped by adding a 
saturated solution of Na2CO3 (1.8 mL) and H2O (10 mL) 
and the crude was centrifuged to remove the protein. The 
aqueous phase was extracted with a CH2Cl2/EtOH (95:5) 
(3  20 mL). The organic phases were combined, dried 
over Na2SO4, and the solvent evaporated under vacuum. 
The crude was purified by flash chromatography (0-2% 
NH3/MeOH) affording the amine as a white solid (17.3 mg, 
0.093 mmol, 62%). Rf (1% NH3/MeOH): 0.20. 1H NMR 
(CD3OD, 300.13 MHz):  1.68-1.81 (m, 1H), 2.07-2.11 (m, 
1H), 2.37-2.45 (m, 1H), 2.77-2.83 (m, 2H), 2.95-3.05 (m, 
1H), 3.12-3.20 (m, 1H), 6.94-7.05 (m, 2H), 7.24 (d, 3JHH= 
7.9 Hz, 1H), 7.35 (d, 3JHH= 7.9 Hz, 1H). 13C NMR (CD3OD, 
75.5 MHz):  22.6 (CH2), 31.3 (CH2), 33.1 (CH2), 49.3 
(CH), 108.2 (C), 111.5 (CH), 118.1 (CH), 119.3 (CH), 
121.5 (CH), 129.0 (C), 134.4 (C), 138.1 (C). []D20= -52.5 
(c 0.8, MeOH) for >97% ee. Lit.[7] for (R)-amine in 99% ee 
[]D20= +62.8 (c 2.0, MeOH) for 99% ee. 
Biotransformations on preparative scale using 
ArRmut11-ωTA: The ketone (500 mg, 2.70 mmol) was 
equally distributed in two Falcon tubes (50 mL) containing 
K-phosphate buffer (pH 7, 100 mM, 13.5 mL), PLP (0.5 
mM) and (R)-1-phenylethylamine (327 mg, 348 µL, 100 
mM). Then, semi purified ArRmut11-ωTA (13.5 mL, 360 
mg crude protein, 216 U) was added to the suspension and 
the reductive amination was carried out at 45 °C in an 
Infors orbital shaker (200 rpm) for 4 h. After that time the 
reactions were combined and basified with a saturated 
solution of Na2CO3 (10 mL) and the mixture was freeze-
dried. The so obtained white powder was resuspended with 
a CH2Cl2/EtOH solution (95:5, 100 mL) and filtered trough 
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a Celite® plug (5 g). The solvent was evaporated under 
reduced pressure affording a solid containing (R)-1-
phenylethylamine. The final high vacuum drying (0.5 mbar, 
40 °C, 4 h) afforded the enantiopure amine (R)-4 as a light-
green solid (485 mg, 2.60 mmol, 96%) containing less than 
2% of (R)-1-phenylethylamine. 
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